MOXEZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MOXEZA (MOXEZA).
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
| Metabolism | Moxifloxacin undergoes hepatic metabolism via glucuronide and sulfate conjugation; negligible metabolism via CYP450 enzymes. Approximately 45% excreted unchanged in urine and 20% in feces. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10% |
| Half-life | Terminal half-life: 12 hours; allows once-daily dosing |
| Protein binding | 40% bound to serum albumin |
| Volume of Distribution | 2.5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 80% |
| Onset of Action | Oral: 1-2 hours; intravenous: within 30 minutes |
| Duration of Action | 24 hours; clinical effect persists due to prolonged half-life |
| Molecular Weight | 401.43 |
400 mg orally once daily with or without food.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | CrCl ≥30 mL/min: no adjustment; CrCl 15-29 mL/min: 400 mg every 48 hours; CrCl <15 mL/min or hemodialysis: 400 mg every 96 hours. |
| Liver impairment | Child-Pugh Class A and B: no adjustment; Child-Pugh Class C: not recommended due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients <18 years. |
| Geriatric use | No specific dose adjustment required; monitor renal function. |
| 1st trimester | Avoid. Inadequate human data; animal studies show reproductive toxicity at clinically relevant doses. Moxeza (moxifloxacin) is a fluoroquinolone associated with arthropathy in immature animals. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid. Same risks as first trimester; potential fetal cartilage damage. Use only if no safer alternative. |
| 3rd trimester | Avoid. Risk of fetal/neonatal joint damage and CNS effects. Avoid near term due to potential for infant toxicity. |
Clinical note
Comprehensive clinical and safety monograph for MOXEZA (MOXEZA).
| Placental transfer | Moxifloxacin crosses the placenta. Human data limited; however, fluoroquinolones achieve measurable concentrations in fetal tissues. Animal studies show transplacental passage. |
| Breastfeeding | Moxifloxacin is excreted into breast milk in low concentrations, but significant infant exposure may occur with maternal doses. Fluoroquinolones are not recommended during breastfeeding due to potential for arthropathy and CNS effects in nursing infants. Alternative agents preferred. If used, monitor infant for diarrhea, rash, or joint abnormalities. |
■ FDA Black Box Warning
Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis.
| Serious Effects |
Hypersensitivity to moxifloxacin or any fluoroquinoloneHistory of tendinopathy or tendon rupture with fluoroquinolone usePregnancy (avoid unless no safer alternative)Lactation (avoid unless no safer alternative)Pediatric patients <18 years (except for specific approved indications)
| Precautions | Tendonitis and tendon rupture, peripheral neuropathy, CNS effects (including seizures and increased intracranial pressure), QT prolongation, hypersensitivity reactions, blood glucose disturbances, Clostridium difficile-associated diarrhea, photosensitivity, and exacerbation of myasthenia gravis. |
| Food/Dietary | No significant food interactions. Systemic absorption is minimal. Avoid alcohol if concurrent oral fluoroquinolones are used, but not specific to ophthalmic route. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Moxeza (moxifloxacin ophthalmic) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Systemic exposure after ophthalmic administration is minimal; however, systemic fluoroquinolones have been associated with arthropathy in juvenile animals. Based on animal data, moxifloxacin is not teratogenic at doses up to 500 mg/kg/day in rats and rabbits, but fetal toxicity (minor skeletal variations) occurred at maternally toxic doses. Risk to the fetus cannot be ruled out; use only if potential benefit justifies potential risk. |
| Fetal Monitoring | No specific monitoring required for ophthalmic use due to low systemic absorption. However, if used systemically, monitor for signs of tendinitis or tendon rupture, QT prolongation (ECG if risk factors), and central nervous system effects. For ophthalmic use, monitor for ocular adverse effects (e.g., conjunctival irritation, keratitis). |
| Fertility Effects | Fluoroquinolones, including moxifloxacin, have not been associated with impaired fertility in animal studies. No specific human data are available for ophthalmic use regarding fertility effects. Systemic fluoroquinolones may reduce fertility by affecting spermatogenesis, but this has not been reported for moxifloxacin. |
| Clinical Pearls | Moxeza (moxifloxacin ophthalmic solution) is a fluoroquinolone antibiotic for bacterial conjunctivitis. Use with caution in patients with a history of tendon disorders or QTc prolongation. Avoid in children under 1 year due to potential joint toxicity. Administer 1 drop in affected eye(s) 3 times daily for 7 days. Monitor for corneal perforation in patients with corneal ulcer or epithelial defect. |
| Patient Advice | Wash hands before and after each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation and wait 15 minutes before reinserting. · Complete the full course even if symptoms improve. · Temporary blurred vision may occur; do not drive or operate machinery until vision clears. · Report persistent eye pain, discharge, or vision changes to your doctor. |